Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2026)

Taysha Gene Therapies has disclosed Operating Leases across 5 years of filings, most recently posting $17.8 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $17.8 million, up 3.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.8 million (up 3.94% YoY), and the FY2025 annual result was $18.2 million, up 4.67% from the prior year.
• Operating Leases came in at $17.8 million for Q1 2026 at Taysha Gene Therapies, down from $18.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $20.4 million in Q4 2022 to a low of $16.5 million in Q3 2025.
• The 5-year median for Operating Leases is $18.2 million (2024), against an average of $18.3 million.
• Across the five-year window, Operating Leases decreased 8.4% in 2024 and climbed 4.67% in 2025, its largest moves.
• Taysha Gene Therapies' Operating Leases stood at $20.4 million in 2022, then dropped by 7.27% to $19.0 million in 2023, then declined by 8.4% to $17.4 million in 2024, then climbed by 4.67% to $18.2 million in 2025, then declined by 2.23% to $17.8 million in 2026.
• The last three Operating Leases figures came in at $17.8 million (Q1 2026), $18.2 million (Q4 2025), and $16.5 million (Q3 2025), per Business Quant data.